Being able to base a diagnosis on the analysis of gene expression signatures in sample material taken at a distance from the site of the disease, such as peripheral blood, has clear advantages for both patients and clinicians. Most competitors that are developing products based on gene expression use sample material taken from the site of the disease, namely tissue samples obtained by biopsy. This traditional approach has severe limitations. For example, there has to be a suspicion of the disease, which is not required with DiaGenic’s concept. DiaGenic also has a significant advantage in cases where it is impossible or extremely difficult to take samples from the site of the disease itself. This is particularly important with neuro-degenerative diseases, such as Alzheimer’s disease, and various forms of cancer - diseases where today we lack good diagnostic tools. Against this background DiaGenic has chosen to focus on the two diseases, breast cancer and Alzheimer’s disease.
Gene Expression Signatures from peripheral blood introduce a new era in patient friendly diagnostics
 |
